TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual MeetingBusiness Wire • 06/12/23
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver MetastasesBusiness Wire • 04/20/23
TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology BusinessBusiness Wire • 02/21/23
TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 StudiesBusiness Wire • 02/16/23
TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research DevelopmentsBusiness Wire • 12/15/22
MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of StockholdersGlobeNewsWire • 12/08/22
TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical StudiesBusiness Wire • 11/21/22
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition CorporationBusiness Wire • 11/14/22
MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business CombinationGlobeNewsWire • 03/10/22
Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021PRNewsWire • 01/06/22
Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition CorporationPRNewsWire • 09/09/21
Memic Going Public Via SPAC: What Investors Should Know About This Medical Device CompanyBenzinga • 08/13/21
Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business CombinationPRNewsWire • 08/13/21